IDX — Integral Diagnostics Income Statement
0.000.00%
Last trade - 00:00
- AU$576.56m
- AU$920.06m
- AU$440.79m
- 72
- 44
- 38
- 53
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 232 | 276 | 351 | 361 | 441 |
Cost of Revenue | |||||
Gross Profit | 222 | 263 | 334 | 342 | 420 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 197 | 232 | 297 | 328 | 392 |
Operating Profit | 35.4 | 43.5 | 53.8 | 33.2 | 48.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 30.6 | 35.3 | 45.2 | 22.6 | 30.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 21 | 23 | 31.3 | 14.6 | 25 |
Net Income Before Extraordinary Items | |||||
Net Income | 21 | 23 | 31.3 | 14.6 | 25 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 21 | 23 | 31.3 | 14.6 | 25 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.141 | 0.107 | 0.127 | 0.086 | 0.075 |
Dividends per Share |